✦ LIBER ✦

A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease

✍ Scribed by Dr Milind P. Sovani, Christopher I. Whale, Anne. E. Tattersfield

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-Acting β2Agonists in the Management

✍ Dr Mario Cazzola, Claudio Ferdinando Donner 📂 Article 📅 2000 🏛 Springer International Publishing AG 🌐 English ⚖ 228 KB

Benefit-Risk Assessment of Long-Acting β

✍ Catherine M. Jackson, Brian Lipworth 📂 Article 📅 2004 🏛 Springer International Publishing AG 🌐 English ⚖ 225 KB

Indacaterol : a new long-acting β2-agoni

✍ Steiropoulos, Paschalis; Papanas, Nikolaos; Nena, Evangelia; Bouros, Demosthenes 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 304 KB

Economic evaluation of treating chronic

✍ Yves M. Gagnon; Adrian R. Levy; Michael D. Spencer; Judith S. Hurley; Floyd J. F 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 805 KB

The effect of inhaled β2-agonists on cli

✍ Mahler, Donald A. 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 85 KB

Management of Asthma and Chronic Obstruc

✍ Mapel, Douglas W.; Roberts, Melissa H. 📂 Article 📅 2014 🏛 Springer International Publishing AG 🌐 English ⚖ 866 KB